Last Week Endocyte, Inc. (NASDAQ:ECYT) Ratings

May 16, 2018 - By Mary Markley

During 2017 Q4 the big money sentiment increased to 1.36. That’s change of 1.04, from 2017Q3’s 0.32. 11 investors sold all, 14 reduced holdings as Endocyte, Inc. ratio improved. 15 increased positions while 19 funds bought positions. Funds hold 19.91 million shares thus 140.76% more from 2017Q3’s 8.27 million shares.
Citigroup Inc stated it has 0% of its capital in Endocyte, Inc. (NASDAQ:ECYT). Deutsche Fincl Bank Ag, Germany-based fund reported 615 shs. Geode Cap Management owns 241,498 shs or 0% of their US capital. Partner Fund Management Ltd Partnership, California-based fund reported 3.44 million shs. Weiss Asset Management Ltd Partnership owns 14,342 shs. Leisure Mngmt reported 28,304 shs. Axa invested in 0% or 23,500 shs. Bessemer Grp stated it has 0% of its capital in Endocyte, Inc. (NASDAQ:ECYT). State Street Corporation accumulated 17,079 shs or 0% of the stock. 33,675 were accumulated by Alpine Mngmt Ltd Llc. Jacobs Levy Equity Mngmt invested in 106,641 shs. Barclays Public Limited has 103,109 shs. Perceptive Advsrs Limited Liability Com reported 1.45M shs stake. Prelude Capital Mngmt Ltd invested 0.01% of its capital in Endocyte, Inc. (NASDAQ:ECYT). Bb&T Securities Ltd Llc accumulated 0% or 20,750 shs.

Endocyte, Inc. had 1 sale and 0 insider purchases since March 9, 2018. This’s net activity of $45,677.

Endocyte, Inc. (NASDAQ:ECYT) Ratings Coverage

In total 3 analysts cover Endocyte (NASDAQ:ECYT). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. (NASDAQ:ECYT) has 100% bullish analysts. 3 are the (NASDAQ:ECYT)’s ratings reports on May 16, 2018 according to StockzIntelligence Inc. On Tuesday, February 27 the stock has “Outperform” rating by Cowen & Co. Listed here are Endocyte, Inc. (NASDAQ:ECYT) PTs and latest ratings.

13/04/2018 Broker: Jefferies Rating: Buy New Target: $17 Initiates Coverage On
09/03/2018 Broker: Wells Fargo Rating: Outperform New Target: $20 Initiates Coverage On
27/02/2018 Broker: Cowen & Co Old Rating: Market Perform New Rating: Outperform Upgrade

ECYT hit $12.77 during the last trading session after $0.66 change.Endocyte, Inc. has volume of 860,613 shares. Since May 16, 2017 ECYT has risen 296.90% and is uptrending. ECYT outperformed the S&P500 by 285.35%.

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States.The firm is worth $880.74 million. The firm uses its technology to create novel small molecule drug conjugates and companion imaging agents.Last it reported negative earnings. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer.

A couple more Endocyte, Inc. (NASDAQ:ECYT) news were released by: Benzinga.com which released on May 14, 2018 “26 Stocks Moving In Monday’s Pre-Market Session”, also Globenewswire.com on May 02, 2018 released “Endocyte Announces First Quarter 2018 Earnings Call”, the next Seekingalpha.com is “Endocyte’s (ECYT) CEO Mike Sherman on Q1 2018 Results – Earnings Call Transcript” on May 09, 2018. Globenewswire.com has article titled “Endocyte Provides First Quarter 2018 Financial Results and Operational Update”.

Endocyte, Inc. (NASDAQ:ECYT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.